What is the catalog number for Mazdutide?

The catalog number for Mazdutide is HY-P3375.

What sizes are available for Mazdutide?

Mazdutide is available in the following size(s): 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg.

How many pack sizes does Mazdutide come in?

Mazdutide is available in 6 different pack sizes.

Is Mazdutide in stock?

Mazdutide is currently made to order / not held in immediate stock. Contact us for lead time.

Who manufactures Mazdutide?

Mazdutide is manufactured by QuantiMol.

What is the estimated delivery time for Mazdutide?

Estimated delivery time for Mazdutide is approximately 15 business day(s), depending on your location.

Where can I find the safety data sheet (SDS/MSDS) for Mazdutide?

The safety data sheet for Mazdutide is available here: http://file.medchemexpress.com/batch_PDF/HY-P3375/Mazdutide-SDS-MedChemExpress.pdf.

Mazdutide

Mazdutide (IBI-362; LY-3305677) is a long-acting synthetic oxyntomodulin analog. Mazdutide is also a co-agonist of glucagon-like peptide (GLP-1R) and glucagon receptor (GCGR) . Mazdutide binds human and mouse GCGR (Ki: 17.7 nM and 15.9 nM, respectively) and GLP-1R (Ki: 28.6 nM and 25.1 nM, respectively) and stimulates insulin secretion from mouse islets (EC50: 5.2 nM) . Mazdutide is used in studies of obesity and type 2 diabetes (T2D) [1][2][3].

Product Specifications

CAS Number

2259884-03-0

Product Name Alternative

IBI-362; LY-3305677; OXM-3

UNSPSC

12352209

Target

GCGR; GLP Receptor

Type

Peptides

Related Pathways

GPCR/G Protein

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/mazdutide.html

Purity

99.94

Solubility

H2O : 22.22 mg/mL (ultrasonic; adjust pH to 2 with HCl)

Smiles

C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@@H](C(=O)O)NC(=O)CCCCCCCCCCCCCCCCCCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC5=CNC6=CC=CC=C65)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)NCC(=O)N7CCC[C@H]7C(=O)N[C@@H](CO)C(=O)NCC(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)N)NC(=O)C(C)(C)NC(=O)[C@H](CC8=CNC=N8)N)O

Molecular Formula

C210H322N46O67

Molecular Weight

4563.06

References & Citations

[1]Chen T, et al. The Design and Optimization of Monomeric Multitarget Peptides for the Treatment of Multifactorial Diseases. J Med Chem. 2022 Mar 10;65 (5) :3685-3705.|[2]Jiang H, et al. A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes. Nat Commun. 2022 Jun 24;13 (1) :3613.|[3]Chen Y, Mezo A, Coskun T, et al. 682-P: novel dual glucagon and glucagon-like peptide-1 receptor agonist LY3305677 improves glucose control, reduces body weight, and increases energy expenditure in mice[J]. Diabetes, 2021, 70 (Supplement_1) .